Newsroom

News and safety alerts

868 items

Announcements, product safety communications and regulatory updates.

MedSafetyWeek

#MedSafetyWeek: Always #ReportSideEffects

Dear healthcare professionals, Do you suspect your patient may be experiencing a side effect after receiving a vaccine? By reporting suspected side effects to the National Pharmaceutical Regulatory…

Document attached

MedSafetyWeek

#MedSafetyWeek starts today!

#MedSafetyWeek starts today! Post-market surveillance is an important and vital part of ensuring the safety of any healthcare product like a medicine or vaccine. Throughout the week we are…

Document attached

Announcement Main

Direktif untuk semua produk yang mengandungi mycophenolate (mycophenolate mofetil dan mycophenolic acid): Pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat untuk Pengguna (RiMUP) dengan maklumat keselamatan berkaitan risiko de novo purine synthesis

Direktif Tarikh Direktif untuk semua produk yang mengandungi mycophenolate (mycophenolate mofetil dan mycophenolic acid): Pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat untuk Pengguna…

Document attached

Announcement

UPDATE: NPRA Financial Year End Closure 2021

UPDATE: 3 Jan 2021 @ 1.00 p.m. To all our valued QUEST 3+ users, Due to unforeseen circumstances, payment gateway error is currently under investigation. We apologize for the inconveniences caused…

Announcement

Notice: Update for Enquiry / Complaint Form

Dear Users, Please be informed that there will be changes in the Enquiry / Complaint Form, with enhanced categorization. This is to ensure all enquiries are attended to accordingly. There will be a…

Safety Alerts

Sacubitril/Valsartan: Risk of Psychiatric Events

Overview Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor (ARNi), which is a combination of a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (ARB)…